{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yang H"],"funding":["Yuhan","Ministry of Science, ICT and Future Planning","Ministry of Science and ICT, South Korea"],"pagination":["1406493"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11215075"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15"],"pubmed_abstract":["<h4>Background</h4>Ezetimibe, which lowers cholesterol by blocking the intestinal cholesterol transporter Niemann-Pick C1 like 1, is reported to reduce hepatic steatosis in humans and animals. Here, we demonstrate the changes in hepatic metabolites and lipids and explain the underlying mechanism of ezetimibe in hepatic steatosis.<h4>Methods</h4>We fed Otsuka Long-Evans Tokushima Fatty (OLETF) rats a high-fat diet (60 kcal % fat) with or vehicle (control) or ezetimibe (10 mg kg<sup>-1</sup>) via stomach gavage for 12 weeks and performed comprehensive metabolomic and lipidomic profiling of liver tissue. We used rat liver tissues, HepG2 hepatoma cell lines, and siRNA to explore the underlying mechanism.<h4>Results</h4>In OLETF rats on a high-fat diet, ezetimibe showed improvements in metaboli"],"journal":["Frontiers in pharmacology"],"pubmed_title":["Ezetimibe, Niemann-Pick C1 like 1 inhibitor, modulates hepatic phospholipid metabolism to alleviate fat accumulation."],"pmcid":["PMC11215075"],"funding_grant_id":["E0164503-02","2019R1F1A1061677"],"pubmed_authors":["Yang H","Do IG","Lee CH","Liu KH","Jung ES","Lee Y","Suh DH","Park CY"],"additional_accession":[]},"is_claimable":false,"name":"Ezetimibe, Niemann-Pick C1 like 1 inhibitor, modulates hepatic phospholipid metabolism to alleviate fat accumulation.","description":"<h4>Background</h4>Ezetimibe, which lowers cholesterol by blocking the intestinal cholesterol transporter Niemann-Pick C1 like 1, is reported to reduce hepatic steatosis in humans and animals. Here, we demonstrate the changes in hepatic metabolites and lipids and explain the underlying mechanism of ezetimibe in hepatic steatosis.<h4>Methods</h4>We fed Otsuka Long-Evans Tokushima Fatty (OLETF) rats a high-fat diet (60 kcal % fat) with or vehicle (control) or ezetimibe (10 mg kg<sup>-1</sup>) via stomach gavage for 12 weeks and performed comprehensive metabolomic and lipidomic profiling of liver tissue. We used rat liver tissues, HepG2 hepatoma cell lines, and siRNA to explore the underlying mechanism.<h4>Results</h4>In OLETF rats on a high-fat diet, ezetimibe showed improvements in metaboli","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-22T12:02:58.882Z","creation":"2025-04-06T00:14:08.673Z"},"accession":"S-EPMC11215075","cross_references":{"pubmed":["38953111"],"doi":["10.3389/fphar.2024.1406493"]}}